| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
In a concentration-dependent manner, bromfenac (0-80 μg/mL; 24 h) suppresses the epithelial-to-mesenchymal transition of HLEC-B3 caused by transforming growth factor-β2 [2]. The transforming growth factor-β2-induced epithelial-to-mesenchymal transition in the human anterior capsule is inhibited by bromfenac (80 μg/Ml; 48 h) [2].
|
|---|---|
| ln Vivo |
In rats, bromfenac (0.0032-3.16%; 100 or 200 μL; applied to the back) demonstrated notable antibacterial action at doses as low as 0.1% (4 hours prior to treatment) or 0.32% (18 hours prior to treatment). an increase in inflammation [3]. In rats, the application of 100 μL of bromfenac (0.032-3.16%) results in dose-dependent anti-inflammatory effects [3]. When administered directly to guinea pigs' UV-exposed skin regions, bromfenac (0.032-1.0%; 50 μL) was 26 times more effective than indomethacin at preventing erythema [3]. Rats' paw volume of both hindlimbs decreases in a dose- and time-dependent manner when bromfenac (0.0032-0.1%; 50 μL) is administered to the uninjected paw four hours a day, five days a week [3]. When administered topically to the abdomen, bromfenac (0.32%; 50 μL) dramatically prevents belly contractions in mice given acetylcholine [3]. When applied twice daily for four weeks, 1 μL (0.09%) of bromfenac eye drops per eye partially lowers corneal staining, which slows down after four weeks [4].
|
| Cell Assay |
Cell viability assay[2]
Cell Types: Transforming growth factor-β2-treated human anterior capsule Tested Concentrations: 80 μg/mL Incubation Duration: 48 hrs (hours) Experimental Results: Transforming growth factor-β2-induced epithelial-mesenchymal transition was inhibited in primary LECs . Cell migration assay[2] Cell Types: HLEC-B3 Cell Tested Concentrations: 0, 20, 40, 60 and 80 μg/mL Incubation Duration: 24 hrs (hours) Experimental Results: Inhibition of transforming growth factor-β2-induced cell migration in HLEC-B3 cells, and demonstrated inhibition of overexpression of epithelial-mesenchymal transition markers. |
| Animal Protocol |
Animal/Disease Models: Male SD (SD (Sprague-Dawley)) rats (150-250 g) injected with carrageenan [3]
Doses: 0.0032, 0.01, 0.032, 0.1, 0.32, 1.0, 3.16% (100 or 200 μL) Route of Administration: 1 Carrageenan injected on back - 72 hrs (hrs (hours)) before injection Experimental Results: Significant anti-inflammatory activity was produced when applied at 0.32% 1, 2 and 4 hrs (hrs (hours)) before carrageenan challenge. Carrageenan is effective when applied 1 or 4 hrs (hrs (hours)) before challenge, but not 0.2% when applied 24 hrs (hrs (hours)) (or more) before challenge. Animal/Disease Models: Male injected with Salin or BTX-B[4] Doses: 1 μL (0.09%) per eye Route of Administration: eye drops; 1 μL (0.09%) per eye; twice a day; 4-week Experimental Results: Corneal fluorescein staining scores improved 4 weeks after treatment. |
| References |
[1]. Tetsuo Kida, et al. Pharmacokinetics and efficacy of topically applied nonsteroidal anti-inflammatory drugs in retinochoroidal tissues in rabbits. PLoS One. 2014 May 5;9(5):e96481.
[2]. Xiaobo Zhang, et al. Drug-eluting intraocular lens with sustained bromfenac release for conquering posterior capsular opacification. Bioact Mater. 2021 Jul 23;9:343-357. [3]. Nolan JC, et, al. The topical anti-inflammatory and analgesic properties of bromfenac in rodents. Agents Actions. 1988 Aug; 25(1-2): 77-85. [4]. Kaevalin Lekhanont, et al. Effects of topical anti-inflammatory agents in a botulinum toxin B-induced mouse model of keratoconjunctivitis sicca. J Ocul Pharmacol Ther. 2007 Feb;23(1):27-34. |
| Molecular Formula |
C30H28BR2N2NA2O9
|
|---|---|
| Molecular Weight |
766.35
|
| CAS # |
120638-55-3
|
| Related CAS # |
Bromfenac sodium;91714-93-1;Bromfenac;91714-94-2
|
| SMILES |
[O-]C(CC1=CC=CC(C(C2=CC=C(Br)C=C2)=O)=C1N)=O.[Na+].[1.5H2O]
|
| Synonyms |
AHR10282B; AHR 10282B
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~260.98 mM)
H2O : ≥ 100 mg/mL (~260.98 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.52 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.52 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 33.33 mg/mL (86.98 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3049 mL | 6.5244 mL | 13.0489 mL | |
| 5 mM | 0.2610 mL | 1.3049 mL | 2.6098 mL | |
| 10 mM | 0.1305 mL | 0.6524 mL | 1.3049 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
